AlphaTON Capital and Subsidiary Cyncado Therapeutics Pioneer Convergence of Digital Assets and Oncology Innovation: Exploring Tokenization Framework for Mesothelioma Program as it Advances Toward Q1 2026 First Patient Dosing
Globenewswireยท2025-10-08 11:16
Landmark Initiative Positions AlphaTON at Forefront of Decentralized Science (DeSci) Movement, Leveraging TON Infrastructure to Accelerate Life-Saving Cancer ResearchDover, DE, Oct. 08, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (Nasdaq: ATON) ("AlphaTON" or the "Company"), alongside its wholly owned oncology subsidiary Tarus Therapeutics, LLC (dba Cyncado Therapeutics) ("Cyncado"), today announced a groundbreaking non-binding letter of intent (LOI) to evaluate tokenization of single-indication economic ...